Header Logo

Connection

Afaaf Liberty to Protease Inhibitors

Back to Details
This is a "connection" page, showing publications Afaaf Liberty has written about Protease Inhibitors.
Afaaf Liberty
Connection Strength
0,051
Protease Inhibitors
  1. Once-daily dolutegravir-based antiretroviral therapy in infants and children living with HIV from age 4 weeks: results from the below 14 kg cohort in the randomised ODYSSEY trial. Lancet HIV. 2022 09; 9(9):e638-e648.
    View in: PubMed
    Score: 0,051
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.